User menu

Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians

Bibliographic reference Hermans, Michel ; Fruchart, Jean-Charles. Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians. In: Therapeutic Advances in Chronic Disease, Vol. 2, no.5, p. 307-323 (2011)
Permanent URL http://hdl.handle.net/2078.1/132404
  1. Adiels M., Olofsson S.-O., Taskinen M.-R., Boren J., Overproduction of Very Low-Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome, 10.1161/atvbaha.107.160192
  2. Ahmad Jamal, Khan Abdur Rahman, Ahmed Faiz, Siddiqui Sabah, Non-HDL cholesterol versus Apolipoprotein B in the identification of dyslipidemic phenotypes associated with cardiovascular risk in type 2 diabetic dyslipoproteinemia, 10.1016/j.dsx.2006.11.002
  3. Alberti K.G.M.M., Eckel R. H., Grundy S. M., Zimmet P. Z., Cleeman J. I., Donato K. A., Fruchart J.-C., James W. P. T., Loria C. M., Smith S. C., Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity, 10.1161/circulationaha.109.192644
  4. Introduction, 10.2337/dc10-s001
  5. Assmann Gerd, Cullen Paul, Fruchart Jean-Charles, Greten Heiner, Naruszewicz Marek, Olsson Anders, Paoletti Rodolfo, Riesen Walter, Stoll Monika, Tikkanen Matti, von Eckardstein Arnold, Implications of emerging risk factors for therapeutic intervention, 10.1016/j.numecd.2005.06.011
  6. Assmann G., Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Munster (PROCAM) Study, 10.1161/hc0302.102575
  7. Assmann G., Schulte H., Cullen P., Seedorf U., Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study, 10.1111/j.1365-2362.2007.01888.x
  8. Assmann G, Schulte H, Seedorf U, Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study, 10.1038/ijo.2008.29
  9. Ballantyne C.M., Am Heart J, 151, e1 (2006)
  10. Ballantyne Christie M., Raichlen Joel S., Cain Valerie A., Statin Therapy Alters the Relationship Between Apolipoprotein B and Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein Cholesterol Targets in High-Risk Patients, 10.1016/j.jacc.2008.04.052
  11. Barter Philip, Gotto Antonio M., LaRosa John C., Maroni Jaman, Szarek Michael, Grundy Scott M., Kastelein John J.P., Bittner Vera, Fruchart Jean-Charles, HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events, 10.1056/nejmoa064278
  12. Bittner Vera, Johnson B. Delia, Zineh Issam, Rogers William J., Vido Diane, Marroquin Oscar C., Bairey-Merz C. Noel, Sopko George, The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia, 10.1016/j.ahj.2008.11.014
  13. Blasiole Daniel A., Davis Roger A., Attie Alan D., The physiological and molecular regulation of lipoprotein assembly and secretion, 10.1039/b700706j
  14. Bonetti P, Statin effects beyond lipid lowering—are they clinically relevant?, 10.1016/s0195-668x(02)00419-0
  15. Bonora E., Targher G., Formentini G., Calcaterra F., Lombardi S., Marini F., Zenari L., Saggiani F., Poli M., Perbellini S., Raffaelli A., Gemma L., Santi L., Bonadonna R. C., Muggeo M., The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study, 10.1046/j.1464-5491.2003.01068.x
  16. Brites Fernando D, Bonavita Carla D, De Geitere Catherine, Cloës Marcelo, Delfly Bernard, Yael Mario J, Fruchart Jean-Charles, Wikinski Regina W, Castro Graciela R, Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels, 10.1016/s0021-9150(99)00452-9
  17. Brown Greg, Albers John J., Fisher Lloyd D., Schaefer Susan M., Lin Jiin-Tarng, Kaplan Cheryl, Zhao Xue-Qiao, Bisson Brad D., Fitzpatrick Virginia F., Dodge Harold T., Regression of Coronary Artery Disease as a Result of Intensive Lipid-Lowering Therapy in Men with High Levels of Apolipoprotein B, 10.1056/nejm199011083231901
  18. Bruno G., Merletti F., Biggeri A., Bargero G., Ferrero S., Runzo C., Prina Cerai S., Pagano G., Cavallo-Perin P., Metabolic Syndrome as a Predictor of All-Cause and Cardiovascular Mortality in Type 2 Diabetes: The Casale Monferrato Study, 10.2337/diacare.27.11.2689
  19. Brunzell John D., Davidson Michael, Furberg Curt D., Goldberg Ronald B., Howard Barbara V., Stein James H., Witztum Joseph L., Lipoprotein Management in Patients With Cardiometabolic Risk, 10.1016/j.jacc.2008.02.034
  20. Buyken Anette E., von Eckardstein Arnold, Schulte Helmut, Cullen Paul, Assmann Gerd, Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study, 10.1097/hjr.0b013e3280142037
  21. Carey Vincent J., Bishop Louise, Laranjo Nancy, Harshfield Benjamin J., Kwiat Carolyn, Sacks Frank M., Contribution of High Plasma Triglycerides and Low High-Density Lipoprotein Cholesterol to Residual Risk of Coronary Heart Disease After Establishment of Low-Density Lipoprotein Cholesterol Control, 10.1016/j.amjcard.2010.05.002
  22. Chapman M. John, Redfern Jan S., McGovern Mark E., Giral Philippe, Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk, 10.1016/j.pharmthera.2010.01.008
  23. Coleman R. L., Stevens R. J., Retnakaran R., Holman R. R., Framingham, SCORE, and DECODE Risk Equations Do Not Provide Reliable Cardiovascular Risk Estimates in Type 2 Diabetes, 10.2337/dc06-1358
  24. Colhoun Helen M, Betteridge D John, Durrington Paul N, Hitman Graham A, W Neil H Andrew, Livingstone Shona J, Thomason Margaret J, Mackness Michael I, Charlton-Menys Valentine, Fuller John H, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial, 10.1016/s0140-6736(04)16895-5
  25. Cordero Alberto, Andrés Eva, Ordoñez Beatriz, León Montserrat, Laclaustra Martín, Grima Alberto, Luengo Emilio, Moreno José, Bes María, Pascual Isaac, Civeira Fernando, Pocoví Miguel, Alegría Eduardo, Casasnovas José A., Usefulness of Triglycerides-to–High-Density Lipoprotein Cholesterol Ratio for Predicting the First Coronary Event in Men, 10.1016/j.amjcard.2009.07.008
  26. Cordero Alberto, Laclaustra Martín, León Montserrat, Casasnovas José A., Grima Alberto, Luengo Emilio, Ordoñez Beatriz, Bergua Clara, Bes María, Pascual Isaac, Alegría Eduardo, Comparison of Serum Lipid Values in Subjects With and Without the Metabolic Syndrome, 10.1016/j.amjcard.2008.03.079
  27. Costet Philippe, Molecular pathways and agents for lowering LDL-cholesterol in addition to statins, 10.1016/j.pharmthera.2010.02.006
  28. da Luz P.L., Clinics (Sao Paulo), 63, 427 (2008)
  29. Damani Samir B., Topol Eric J., Future Use of Genomics in Coronary Artery Disease, 10.1016/j.jacc.2007.07.062
  30. Davidson Michael H., Reducing Residual Risk for Patients on Statin Therapy: The Potential Role of Combination Therapy, 10.1016/j.amjcard.2005.08.002
  31. Davignon Jean, Cohn Jeffrey S., Triglycerides: a risk factor for coronary heart disease, 10.1016/0021-9150(96)05858-3
  32. deGoma Emil M., Leeper Nicholas J., Heidenreich Paul A., Clinical Significance of High-Density Lipoprotein Cholesterol in Patients With Low Low-Density Lipoprotein Cholesterol, 10.1016/j.jacc.2007.07.086
  33. deGoma Emil M., Rader Daniel J., Novel HDL-directed pharmacotherapeutic strategies, 10.1038/nrcardio.2010.200
  34. Dehout Florence, Haumont Sophie, Gaham Nezli, Amoussou-Guenou K. Daniel, Hermans Michel P., Metabolic syndrome in Bantu subjects with type 2 diabetes from sub-Saharan extraction, 10.1016/j.dsx.2007.11.008
  35. Denke M. A., Weighing in Before the Fight: Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Versus Apolipoprotein B as the Best Predictor for Coronary Heart Disease and the Best Measure of Therapy, 10.1161/circulationaha.105.588178
  36. Dobiás̆ová Milada, Frohlich Jiri, The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate inapob-lipoprotein-depleted plasma (FERHDL), 10.1016/s0009-9120(01)00263-6
  37. J. Ducobu, A. Scheen, L. Van Gaal, B. Velkeniers, M. Hermans, Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates, 10.2143/ac.63.2.2029534
  38. Eichler Klaus, Puhan Milo A., Steurer Johann, Bachmann Lucas M., Prediction of first coronary events with the Framingham score: A systematic review, 10.1016/j.ahj.2007.02.027
  39. Fioretto Paola, Dodson Paul M., Ziegler Dan, Rosenson Robert S., Residual microvascular risk in diabetes: unmet needs and future directions, 10.1038/nrendo.2009.213
  40. Forrester James S., Redefining Normal Low-Density Lipoprotein Cholesterol, 10.1016/j.jacc.2009.11.090
  41. Friedewald Vincent E., Ballantyne Christie M., Davidson Michael H., Guyton John R., Roberts William C., The Editor's Roundtable: Lipid Management Beyond Statins—Reducing Residual Cardiovascular Risk, 10.1016/j.amjcard.2008.06.028
  42. Fruchart Jean-Charles, Peroxisome proliferator-activated receptor-alpha (PPARα): At the crossroads of obesity, diabetes and cardiovascular disease, 10.1016/j.atherosclerosis.2009.03.008
  43. Fruchart J.C., Int J Diab Mellitus, 30 (2010)
  44. Fruchart Jean-Charles, Duriez Patrick, HDL and triglyceride as therapeutic targets : , 10.1097/00041433-200212000-00003
  45. Fruchart J.C., Circulation, 109, III15 (2004)
  46. Fruchart J.C., Sacks F.M., Hermans M.P., , Implications of the ACCORD Lipid study: perspective from the Residual Risk Reduction Initiative (R3i), 10.1185/03007995.2010.489341
  47. Fruchart Jean-Charles, Sacks Frank M, Hermans Michel P, Assmann Gerd, Brown W Virgil, Ceska Richard, Chapman M John, Dodson Paul M, Fioretto Paola, Ginsberg Henry N, Kadowaki Takashi, Lablanche Jean-Marc, Marx Nikolaus, Plutzky Jorge, Reiner Zeljko, Rosenson Robert S, Staels Bart, Stock Jane K, Sy Rody, Wanner Christoph, Zambon Alberto, Zimmet Paul, The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients, 10.3132/dvdr.2008.046
  48. Fruchart Jean-Charles, Sacks Frank, Hermans Michel P., Assmann Gerd, Brown W. Virgil, Ceska Richard, Chapman M. John, Dodson Paul M., Fioretto Paola, Ginsberg Henry N., Kadowaki Takashi, Lablanche Jean-Marc, Marx Nikolaus, Plutzky Jorge, Reiner Željko, Rosenson Robert S., Staels Bart, Stock Jane K., Sy Rody, Wanner Christoph, Zambon Alberto, Zimmet Paul, The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia, 10.1016/j.amjcard.2008.10.002
  49. Gæde Peter, Lund-Andersen Henrik, Parving Hans-Henrik, Pedersen Oluf, Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes, 10.1056/nejmoa0706245
  50. Gæde Peter, Vedel Pernille, Larsen Nicolai, Jensen Gunnar V.H., Parving Hans-Henrik, Pedersen Oluf, Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes, 10.1056/nejmoa021778
  51. Genest Jacques, McPherson Ruth, Frohlich Jiri, Anderson Todd, Campbell Norm, Carpentier André, Couture Patrick, Dufour Robert, Fodor George, Francis Gordon A., Grover Steven, Gupta Milan, Hegele Robert A., Lau David C., Leiter Lawrence, Lewis Gary F., Lonn Eva, John Mancini G.B., Ng Dominic, Pearson Glen J., Sniderman Allan, Stone James A., Ur Ehud, 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations, 10.1016/s0828-282x(09)70715-9
  52. , Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., Dallongeville J., De Backer G., Ebrahim S., Gjelsvik B., Herrmann-Lingen C., Hoes A., Humphries S., Knapton M., Perk J., Priori S. G., Pyorala K., Reiner Z., Ruilope L., Sans-Menendez S., Scholte op Reimer W., Weissberg P., Wood D., Yarnell J., Zamorano J. L., Walma E., Fitzgerald T., Cooney M. T., Dudina A., Vahanian A., Camm J., De Caterina R., Dean V., Dickstein K., Funck-Brentano C., Filippatos G., Hellemans I., Kristensen S. D., McGregor K., Sechtem U., Silber S., Tendera M., Widimsky P., Zamorano J. L., Hellemans I., Altiner A., Bonora E., Durrington P. N., Fagard R., Giampaoli S., Hemingway H., Hakansson J., Kjeldsen S. E., Larsen M. L., Mancia G., Manolis A. J., Orth-Gomer K., Pedersen T., Rayner M., Ryden L., Sammut M., Schneiderman N., Stalenhoef A. F., Tokgozoglu L., Wiklund O., Zampelas A., , , , European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts), 10.1093/eurheartj/ehm316
  53. Grundy S. M., Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement, 10.1161/circulationaha.105.169404
  54. Grundy S. M., Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines, 10.1161/01.cir.0000133317.49796.0e
  55. Haffner Steven M., Lehto Seppo, Rönnemaa Tapani, Pyörälä Kalevi, Laakso Markku, Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction, 10.1056/nejm199807233390404
  56. Hanak Viktor, Munoz Julian, Teague Joe, Stanley Alfred, Bittner Vera, Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype B, 10.1016/j.amjcard.2004.03.069
  57. Hermans Michel P, Diabetic macro- and microvascular disease in type 2 diabetes, 10.3132/dvdr.2007.019
  58. P. Hermans Michel, Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD, 10.2174/157340310791162686
  59. Hermans Michel P., Amoussou-Guenou K. Daniel, Ahn Sylvie A., Rousseau Michel F., Impact of metabolic syndrome and its severity on microvascular complications in type 2 diabetes, 10.1016/j.dsx.2010.05.021
  60. Hermans Michel P., Ahn Sylvie A., Rousseau Michel F., The non-HDL-C/HDL-C ratio provides cardiovascular risk stratification similar to the ApoB/ApoA1 ratio in diabetics: Comparison with reference lipid markers, 10.1016/j.dsx.2006.11.003
  61. Hermans Michel P., Ahn Sylvie A., Rousseau Michel F., Cardiometabolic phenotype and UKPDS risk in male type 2 diabetic patients with obstructive sleep apnoea, 10.1016/j.dsx.2008.10.011
  62. Hermans Michel P., Ahn Sylvie A., Rousseau Michel F., Erectile dysfunction, microangiopathy and UKPDS risk in type 2 diabetes, 10.1016/j.diabet.2009.06.003
  63. Hermans Michel P, Ahn Sylvie A, Rousseau Michel F, log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males, 10.1186/1475-2840-9-88
  64. Hermans Michel P., Castro Cabezas Manuel, Strandberg Timo, Ferrières Jean, Feely John, Elisaf Moses, Michel Georges, Sansoy Vedat, Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries, 10.1185/03007990903500565
  65. Hermans Michel P, Fruchart Jean-Charles, Reducing residual vascular risk in patients with atherogenic dyslipidemia: where do we go from here?, 10.2217/clp.10.65
  66. Hermans M., Muls E., Michel G., Elisaf M., Brotons C., Matthys A., P132 OPTIMAL TYPE 2 DIABETES MANAGEMENT INCLUDING BENCHMARKING AND STANDARD TREATMENT. BASELINE EUROPEAN RESULTS, 10.1016/s1567-5688(10)70199-9
  67. Hermans Michel P, Sacks Frank M, Ahn Sylvie A, Rousseau Michel F, Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence, 10.1186/1475-2840-10-20
  68. Jones Peter H., Expert Perspective: Reducing Cardiovascular Risk in Metabolic Syndrome and Type 2 Diabetes Mellitus Beyond Low-Density Lipoprotein Cholesterol Lowering, 10.1016/j.amjcard.2008.09.074
  69. Jun Min, Foote Celine, Lv Jicheng, Neal Bruce, Patel Anushka, Nicholls Stephen J, Grobbee Diederick E, Cass Alan, Chalmers John, Perkovic Vlado, Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis, 10.1016/s0140-6736(10)60656-3
  70. Juutilainen A., Lehto S., Ronnemaa T., Pyorala K., Laakso M., Type 2 Diabetes as a "Coronary Heart Disease Equivalent": An 18-year prospective population-based study in Finnish subjects, 10.2337/diacare.28.12.2901
  71. Kannel William B., Vasan Ramachandran S., Keyes Michelle J., Sullivan Lisa M., Robins Sander J., Usefulness of the Triglyceride–High-Density Lipoprotein Versus the Cholesterol–High-Density Lipoprotein Ratio for Predicting Insulin Resistance and Cardiometabolic Risk (from the Framingham Offspring Cohort), 10.1016/j.amjcard.2007.09.109
  72. Katcher Heather I., Hill Alison M., Lanford Julie L.G., Yoo Janey S., Kris-Etherton Penny M., Lifestyle Approaches and Dietary Strategies to Lower LDL-Cholesterol and Triglycerides and Raise HDL-Cholesterol, 10.1016/j.ecl.2008.11.010
  73. Kathiresan S., Increased Small Low-Density Lipoprotein Particle Number: A Prominent Feature of the Metabolic Syndrome in the Framingham Heart Study, 10.1161/circulationaha.105.567107
  74. Kim-Dorner Su-Jong, Deuster Patricia A., Zeno Stacey A., Remaley Alan T., Poth Merrily, Should triglycerides and the triglycerides to high-density lipoprotein cholesterol ratio be used as surrogates for insulin resistance?, 10.1016/j.metabol.2009.07.027
  75. Kothari V., Stevens R. J., Adler A. I., Stratton I. M., Manley S. E., Neil H. A., Holman R. R., UKPDS 60: Risk of Stroke in Type 2 Diabetes Estimated by the UK Prospective Diabetes Study Risk Engine, 10.1161/01.str.0000020091.07144.c7
  76. LaRosa John C., Grundy Scott M., Waters David D., Shear Charles, Barter Philip, Fruchart Jean-Charles, Gotto Antonio M., Greten Heiner, Kastelein John J.P., Shepherd James, Wenger Nanette K., Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease, 10.1056/nejmoa050461
  77. Libby Peter, The Forgotten Majority, 10.1016/j.jacc.2005.07.006
  78. Lu W., Resnick H. E., Jablonski K. A., Jones K. L., Jain A. K., Howard Wm. J., Robbins D. C., Howard B. V., Non-HDL Cholesterol as a Predictor of Cardiovascular Disease in Type 2 Diabetes: The Strong Heart Study, 10.2337/diacare.26.1.16
  79. Manninen V., Tenkanen L., Koskinen P., Huttunen J. K., Manttari M., Heinonen O. P., Frick M. H., Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment, 10.1161/01.cir.85.1.37
  80. Mazzone Theodore, Chait Alan, Plutzky Jorge, Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies, 10.1016/s0140-6736(08)60768-0
  81. Mendivil C. O., Zheng C., Furtado J., Lel J., Sacks F. M., Metabolism of Very-Low-Density Lipoprotein and Low-Density Lipoprotein Containing Apolipoprotein C-III and Not Other Small Apolipoproteins, 10.1161/atvbaha.109.197830
  82. , The Metabolic Syndrome Is a Risk Indicator of Microvascular and Macrovascular Complications in Diabetes: Results from Metascreen, a multicenter diabetes clinic-based survey, 10.2337/dc06-0942
  83. Millán Núñez-Cortés Jesús, Montoya Juan Pedro-Botet, Salas Xavier Pintó, Mijares Antonio Hernández, Carey Vincent J., Hermans Michel P., Sacks Frank M., Fruchart Jean-Charles, Estudio REALIST (REsiduAl risk, LIpids and Standard Therapies): Un análisis del Riesgo Residual dependiente del perfil lipídico en el síndrome coronario agudo, 10.1016/j.endonu.2010.10.004
  84. Nicholls Stephen J., Gordon Allan, Johansson Jan, Wolski Kathy, Ballantyne Christie M., Kastelein John J.P., Taylor Allen, Borgman Marilyn, Nissen Steven E., Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease, 10.1016/j.jacc.2010.11.015
  85. Pischon T., Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B in the Prediction of Coronary Heart Disease in Men, 10.1161/circulationaha.104.532499
  86. Polonsky Tamar S., Davidson Michael H., Reducing the Residual Risk of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy With Combination Therapy, 10.1016/j.amjcard.2008.02.051
  87. Ridker Paul M, Danielson Eleanor, Fonseca Francisco A.H., Genest Jacques, Gotto Antonio M., Kastelein John J.P., Koenig Wolfgang, Libby Peter, Lorenzatti Alberto J., MacFadyen Jean G., Nordestgaard Børge G., Shepherd James, Willerson James T., Glynn Robert J., Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein, 10.1056/nejmoa0807646
  88. Rosenson Robert S., Management of non-high-density lipoprotein abnormalities, 10.1016/j.atherosclerosis.2009.05.020
  89. Rosenson Robert S., Davidson Michael H., Pourfarzib Ray, Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk, 10.1016/j.atherosclerosis.2010.03.038
  90. Combination Lipid Therapy in Type 2 Diabetes, 10.1056/nejmc1006407
  91. Sacks F. M., Tonkin A. M., Shepherd J., Braunwald E., Cobbe S., Hawkins C. M., Keech A., Packard C., Simes J., Byington R., Furberg C. D., Effect of Pravastatin on Coronary Disease Events in Subgroups Defined by Coronary Risk Factors : The Prospective Pravastatin Pooling Project, 10.1161/01.cir.102.16.1893
  92. Sadikot S., Hermans M., Here we go again … The metabolic syndrome revisited!, 10.1016/j.dsx.2010.05.011
  93. Sadikot S.M., Misra A., The metabolic syndrome: An exercise in utility or futility?, 10.1016/j.dsx.2006.11.001
  94. Schramm T. K., Gislason G. H., Kober L., Rasmussen S., Rasmussen J. N., Abildstrom S. Z., Hansen M. L., Folke F., Buch P., Madsen M., Vaag A., Torp-Pedersen C., Diabetes Patients Requiring Glucose-Lowering Therapy and Nondiabetics With a Prior Myocardial Infarction Carry the Same Cardiovascular Risk: A Population Study of 3.3 Million People, 10.1161/circulationaha.107.720847
  95. Shepherd J., Barter P., Carmena R., Deedwania P., Fruchart J.-C., Haffner S., Hsia J., Breazna A., LaRosa J., Grundy S., Waters D., , Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes: The Treating to New Targets (TNT) study, 10.2337/dc05-2465
  96. Sniderman A. D., Apolipoprotein B Versus Non-High-Density Lipoprotein Cholesterol: And the Winner Is..., 10.1161/circulationaha.105.583336
  97. Sniderman Allan, Williams Ken, Cobbaert Christa, ApoB versus non-HDL-C: What to do when they disagree, 10.1007/s11883-009-0054-2
  98. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., Fruchart J.-C., Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism, 10.1161/01.cir.98.19.2088
  99. Stevens R. J., Coleman R. L., Adler A. I., Stratton I. M., Matthews D. R., Holman R. R., Risk Factors for Myocardial Infarction Case Fatality and Stroke Case Fatality in Type 2 Diabetes: UKPDS 66, 10.2337/diacare.27.1.201
  100. STEVENS Richard J., KOTHARI Viti, ADLER Amanda I., STRATTON Irene M., HOLMAN Rury R., The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56), 10.1042/cs1010671
  101. Stratton I. M., Cull C. A., Adler A. I., Matthews D. R., Neil H. A. W., Holman R. R., Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75), 10.1007/s00125-006-0297-1
  102. Sulkes Destry, Brown Bruce Gregory, Krauss Ronald M., Segrest Jere P., Sniderman Allan D., Roberts William C., The Editor’s Roundtable: Expanded Versus Standard Lipid Panels in Assessing and Managing Cardiovascular Risk, 10.1016/j.amjcard.2007.12.006
  103. Sumner Anne E., Vega Gloria L., Genovese David J., Finley Karl B., Bergman Richard N., Boston Raymond C., Normal triglyceride levels despite insulin resistance in African Americans: role of lipoprotein lipase, 10.1016/j.metabol.2005.03.001
  104. Volek Jeff S., Fernandez Maria Luz, Feinman Richard D., Phinney Stephen D., Dietary carbohydrate restriction induces a unique metabolic state positively affecting atherogenic dyslipidemia, fatty acid partitioning, and metabolic syndrome, 10.1016/j.plipres.2008.02.003
  105. Waksman Ron, Torguson Rebecca, Kent Kenneth M., Pichard Augusto D., Suddath William O., Satler Lowell F., Martin Brenda D., Perlman Timothy J., Maltais Jo-Ann B., Weissman Neil J., Fitzgerald Peter J., Brewer H. Bryan, A First-in-Man, Randomized, Placebo-Controlled Study to Evaluate the Safety and Feasibility of Autologous Delipidated High-Density Lipoprotein Plasma Infusions in Patients With Acute Coronary Syndrome, 10.1016/j.jacc.2009.12.067
  106. WALLDIUS G., JUNGNER I., The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence, 10.1111/j.1365-2796.2006.01643.x
  107. Walldius Göran, Jungner Ingmar, Holme Ingar, Aastveit Are H, Kolar Werner, Steiner Eugen, High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study, 10.1016/s0140-6736(01)07098-2
  108. Watts Gerald F., Ooi Esther M.M., Chan Dick C., Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo, 10.1016/j.pharmthera.2009.04.005
  109. Wilson Peter W.F., Risk Scores for Prediction of Coronary Heart Disease: An Update, 10.1016/j.ecl.2008.11.001
  110. Yusuf Salim, Hawken Steven, Ôunpuu Stephanie, Dans Tony, Avezum Alvaro, Lanas Fernando, McQueen Matthew, Budaj Andrzej, Pais Prem, Varigos John, Lisheng Liu, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study, 10.1016/s0140-6736(04)17018-9
  111. Zheng C., Khoo C., Furtado J., Sacks F. M., Apolipoprotein C-III and the Metabolic Basis for Hypertriglyceridemia and the Dense Low-Density Lipoprotein Phenotype, 10.1161/circulationaha.109.875807